BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Spriggs MJ, Douglass HM, Park RJ, Read T, Danby JL, de Magalhães FJC, Alderton KL, Williams TM, Blemings A, Lafrance A, Nicholls DE, Erritzoe D, Nutt DJ, Carhart-Harris RL. Study Protocol for "Psilocybin as a Treatment for Anorexia Nervosa: A Pilot Study". Front Psychiatry 2021;12:735523. [PMID: 34744825 DOI: 10.3389/fpsyt.2021.735523] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 1.5] [Reference Citation Analysis]
Number Citing Articles
1 Johnston JN, Kadriu B, Allen J, Gilbert JR, Henter ID, Zarate CA Jr. Ketamine and serotonergic psychedelics: An update on the mechanisms and biosignatures underlying rapid-acting antidepressant treatment. Neuropharmacology 2023;226:109422. [PMID: 36646310 DOI: 10.1016/j.neuropharm.2023.109422] [Reference Citation Analysis]
2 Carhart-Harris RL, Chandaria S, Erritzoe DE, Gazzaley A, Girn M, Kettner H, Mediano PAM, Nutt DJ, Rosas FE, Roseman L, Timmermann C, Weiss B, Zeifman RJ, Friston KJ. Canalization and plasticity in psychopathology. Neuropharmacology 2023;226:109398. [PMID: 36584883 DOI: 10.1016/j.neuropharm.2022.109398] [Reference Citation Analysis]
3 Mastinu A, Anyanwu M, Carone M, Abate G, Bonini SA, Peron G, Tirelli E, Pucci M, Ribaudo G, Oselladore E, Premoli M, Gianoncelli A, Uberti DL, Memo M. The Bright Side of Psychedelics: Latest Advances and Challenges in Neuropharmacology. Int J Mol Sci 2023;24. [PMID: 36674849 DOI: 10.3390/ijms24021329] [Reference Citation Analysis]
4 Ledwos N, Rodas JD, Husain MI, Feusner JD, Castle DJ. Therapeutic uses of psychedelics for eating disorders and body dysmorphic disorder. J Psychopharmacol 2023;37:3-13. [PMID: 36515406 DOI: 10.1177/02698811221140009] [Reference Citation Analysis]
5 Spriggs MJ, Giribaldi B, Lyons T, Rosas FE, Kärtner LS, Buchborn T, Douglass HM, Roseman L, Timmermann C, Erritzoe D, Nutt DJ, Carhart-Harris RL. Body mass index (BMI) does not predict responses to psilocybin. J Psychopharmacol 2023;37:107-16. [PMID: 36373934 DOI: 10.1177/02698811221131994] [Reference Citation Analysis]
6 Lauren S. Otterman. Research into Psychedelic-Assisted Psychotherapy for Anorexia Nervosa Should be Funded. J Bioeth Inq 2022. [PMID: 36534233 DOI: 10.1007/s11673-022-10220-9] [Reference Citation Analysis]
7 Thal SB, Wieberneit M, Sharbanee JM, Skeffington PM, Baker P, Bruno R, Wenge T, Bright SJ. Therapeutic (Sub)stance: Current practice and therapeutic conduct in preparatory sessions in substance-assisted psychotherapy-A systematized review. J Psychopharmacol 2022;:2698811221127954. [PMID: 36263882 DOI: 10.1177/02698811221127954] [Reference Citation Analysis]
8 Ragnhildstveit A, Slayton M, Jackson LK, Brendle M, Ahuja S, Holle W, Moore C, Sollars K, Seli P, Robison R. Ketamine as a Novel Psychopharmacotherapy for Eating Disorders: Evidence and Future Directions. Brain Sciences 2022;12:382. [DOI: 10.3390/brainsci12030382] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 4.0] [Reference Citation Analysis]
9 Kelly JR, Gillan CM, Prenderville J, Kelly C, Harkin A, Clarke G, O'Keane V. Psychedelic Therapy's Transdiagnostic Effects: A Research Domain Criteria (RDoC) Perspective. Front Psychiatry 2021;12:800072. [PMID: 34975593 DOI: 10.3389/fpsyt.2021.800072] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 8.0] [Reference Citation Analysis]